A congressional lawmaker is investigating the role that a former Gilead Sciences (GILD) lobbyist played in the Trump administration and its efforts to develop a payment model for a pricey new Novartis cancer drug.

The focus of the inquiry is Joseph Grogan, who joined the Trump administration in early 2017 as associate director of health programs at the Office of Management and Budget, where he was working on a “pay-for-performance” program for the Novartis (NVS) drug, called Kymriah.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • I wonder if there are viaticals for cancer treatments , which have a chance of success, as it was for HIV patients who are, as we are yet without a cure, going to die?

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy